Penserra Capital Management LLC Genmab A/S Transaction History

Penserra Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$35.87 - $47.12 $39,636 - $52,067	-1,105 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $623 - $730	15 Added 1.38%	1,105 $48,000
Q2 2021 Aug 12, 2021	BUY	$32.88 - $44.57 $328 - $445	10 Added 0.93%	1,090 $44,000
Q1 2021 May 13, 2021	BUY	$30.92 - $44.4 $154 - $222	5 Added 0.47%	1,080 $35,000
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $23,797 - $28,817	707 Added 192.12%	1,075 $43,000
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $4.15 Million - $4.85 Million	-125,381 Reduced 99.71%	368 $13,000
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $2.48 Million - $4.19 Million	123,779 Added 6283.2%	125,749 $4.26 Million
Q1 2020 May 14, 2020	BUY	$17.15 - $25.22 $33,785 - $49,683	1,970 New	1,970 $54,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.